indacterol
FDA delays decision on Novartis’ COPD drug
March 23, 2011Sales and Marketing COPD, Novartis, Onbrez Breezhaler, QAB149, bronchodilator, chronic obstructive pulmonary disease, indacterol
The FDA has delayed its licence decision on Novartis’ once-daily COPD treatment QAB149 by three months. The review process will …
Novartis’ COPD drug recommended for FDA approval
March 10, 2011Sales and Marketing Arcapta Neohaler, COPD, Novartis, Onbrez Breezhaler, QAB143, chronic obstructive pulmonary disease, indacterol
Novartis has won the backing of an FDA advisory committee for its chronic obstructive pulmonary disease (COPD) treatment QAB149. The …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
August 14, 2026
